Status:
UNKNOWN
A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction
Lead Sponsor:
Cui Yimin
Conditions:
Simvastatin Adverse Reaction
Pharmacogenomics
Eligibility:
All Genders
18+ years
Brief Summary
Adverse reactions of simvastatin are mostly slight and transient, however, the incidence of simvastatin-induced hepatic impairment and myopathy are obviously higher in Chinese population than other ra...
Eligibility Criteria
Inclusion
- Patients taking simvastatin therapy
- Signed informed consent.
Exclusion
- Patients not taking simvastatin therapy
- Intolerance or unwillingness to blood sample collection.
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
2200 Patients enrolled
Trial Details
Trial ID
NCT03261908
Start Date
August 1 2018
End Date
December 1 2018
Last Update
May 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034